NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis: 2011 Update. Geneva: World Health Organization; 2011.

  • This publication is provided for historical reference only and the information may be out of date.

This publication is provided for historical reference only and the information may be out of date.

Cover of Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis

Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis: 2011 Update.

Show details

Annex 1Methods for evidence reviews and modelling

Questions for the 2011 update of the Guidelines for the programmatic management of drug-resistant tuberculosis (for Outcomes please see Table 2 in the main text of the Guidelines)

1. At what prevalence of MDR-TB in any group of TB patients is rapid drug-susceptibility testing warranted to detect resistance to rifampicin and isoniazid or rifampicin alone on all patients in the group at the time of TB diagnosis, in order to prescribe appropriate treatment at the outset?

2. Among patients with MDR-TB receiving appropriate treatment in settings with reliable direct microscopy, is monitoring using sputum smear microscopy alone, rather than sputum smear and culture, more or less likely to lead to the outcomes listed in Table 2 of the guidelines?

3-5. When designing regimens for patients with MDR-TB, is the inclusion of specific drugs (with or without documented susceptibility) more or less likely to lead to the outcomes listed in Table 2 of the guidelines?When designing regimens for patients with MDR-TB, is the inclusion of fewer drugs in the regimen (depending on the drug used, the patient's history of its use and isolate susceptibility) more or less likely to lead to the outcomes listed in Table 2 of the guidelines?In patients with MDR-TB, is shorter treatment, compared with the duration currently recommended by WHO, more or less likely to lead to the outcomes listed in Table 2 of the guidelines?

6. In patients with HIV infection and drug-resistant TB receiving antiretroviral therapy, is the use of drugs with overlapping and potentially additive toxicities, compared with their avoidance, more or less likely to lead to the outcomes listed in Table 2 of the guidelines?

7. Among patients with MDR-TB, is ambulatory therapy, compared with inpatient treatment, more or less likely to lead to the outcomes listed in Table 2 of the guidelines?

Copyright © 2011, World Health Organization.

All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: tni.ohw@sredrokoob).

Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html).

Bookshelf ID: NBK148643

Views

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...